×
About 128,868 results

ALLMedicine™ Melanoma Center

Research & Reviews  60,141 results

Regression is significantly associated with outcomes for patients with melanoma.
https://doi.org/10.1016/j.surg.2021.05.010
Surgery Subramanian S, Han G et. al.

Jun 14th, 2021 - The prognostic significance of regression in melanoma is debated. We present a large multicenter study correlating regression with sentinel lymph node metastasis and melanoma-specific survival. The Sentinel Lymph Node Working Group database was re...

Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic st...
https://doi.org/10.1016/j.ejso.2021.06.011
European Journal of Surgical Oncology : the Journal of Th... Helvind NM, Aros Mardones CA et. al.

Jun 14th, 2021 - The use of routine imaging with 18F-FDG PET-CT (PET-CT) in melanoma surveillance is debated and evidence of its diagnostic value and yield in asymptomatic patients is limited. Denmark introduced nationwide routine surveillance with PET-CT in high-...

Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical...
https://doi.org/10.1007/s40257-021-00614-7 10.3322/caac.21590 10.1007/s40257-019-00487-x 10.1002/1097-0142(19930301)71:5<1893::AID-CNCR2820710528>3.0.CO;2-7 10.1111/j.0736-8046.2004.21412.x 10.1001/archderm.1997.03890390083011 10.1111/pde.12838 10.1016/j.jaad.2005.07.034 10.1016/0002-9378(79)90732-4 10.1016/0190-9622(90)70017-C 10.1046/j.1525-1438.2001.01043.x 10.1097/LGT.0000000000000583 10.1002/1097-0142(19950101)75:1<72::AID-CNCR2820750113>3.0.CO;2-G 10.1016/j.jaad.2003.07.026 10.1002/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z 10.1002/(SICI)1097-0142(19961201)78:11<2353::AID-CNCR13>3.0.CO;2-# 10.1016/j.ygyno.2016.04.021 10.2340/00015555-3103 10.3892/ijmm.2014.1659 10.1038/320415a0 10.1002/j.1460-2075.1987.tb02655.x 10.1200/JCO.2006.06.2984 10.1016/j.humpath.2005.03.015 10.1002/cncr.30473 10.1158/1078-0432.CCR-10-2917 10.1097/PGP.0000000000000636 10.1038/nature05661 10.1016/j.cellsig.2005.06.008 10.1038/onc.2009.320 10.1097/LGT.0000000000000142 10.1016/j.jid.2016.06.011 10.1111/j.1365-2133.2010.10185.x 10.1016/j.jid.2016.05.098 10.1016/j.jaad.2014.03.033 10.1111/j.1365-2133.2009.09558.x 10.4161/21645515.2014.983409 10.1097/PGP.0000000000000454 10.1111/cup.13768 10.1158/1078-0432.CCR-16-2126 10.1097/LGT.0000000000000204 10.1245/s10434-014-4215-3 10.1002/1097-0142(19940515)73:10<2626::AID-CNCR2820731026>3.0.CO;2-U 10.1097/00008390-200412000-00012 10.1016/j.ygyno.2013.02.028 10.1111/ced.14068 10.1111/ajd.12298 10.1016/j.det.2010.08.007 10.1097/00008390-200512000-00011 10.1016/S1470-2045(02)00679-4 10.1001/archdermatol.2011.155 10.1159/000323409 10.1097/IGC.0000000000000198 10.1093/annonc/mdz411 10.1111/j.1525-1438.2007.00788.x 10.1016/0090-8258(92)90300-8 10.1016/j.ygyno.2018.04.562 10.1056/NEJMoa1310460 10.1038/bjc.2014.205 10.1016/j.ygyno.2020.09.044 10.1136/ijgc-2019-000936 10.1016/j.ygyno.2012.11.034 10.1016/j.ygyno.2015.02.014 10.1056/NEJMoa1613210 10.1200/JCO.18.02306 10.1097/MD.0000000000008722 10.1097/00000658-199110000-00013 10.1002/cncr.21611 10.1097/00000421-200206000-00016 10.1200/JCO.2000.18.1.158 10.1056/NEJMoa1003466 10.1056/NEJMoa1709684 10.1056/NEJMoa1503093 10.1056/NEJMoa1412690 10.1200/JCO.2013.53.0105 10.1056/NEJMoa1412082 10.1016/S1470-2045(15)70076-8 10.1056/NEJMoa1414428 10.1056/NEJMoa1504030 10.1200/JCO.2016.67.9258 10.1001/jama.2016.4059 10.1016/S1470-2045(15)00083-2 10.1038/s41416-018-0207-6 10.3390/cancers11081213 10.1038/s41577-019-0224-6 10.1182/blood-2017-07-741025 10.1038/sj.bjc.6602529 10.1002/cncr.21834 10.1038/sj.bjc.6604482 10.1001/jama.2011.746 10.1200/JCO.2012.47.7836 10.1200/JCO.2010.33.9275 10.1158/1078-0432.CCR-14-1630 10.1634/theoncologist.2015-0161 10.1093/annonc/mdx079 10.1007/s10637-011-9763-9 10.1016/j.jid.2017.07.839 10.1158/1078-0432.CCR-11-1987 10.1002/cncr.25766 10.1002/cncr.30663 10.1038/ncponc1251 10.1200/JCO.20.00198 10.1016/j.ctrv.2020.102032 10.1056/NEJMoa1802357 10.1056/NEJMoa1611299 10.1056/NEJMoa1709030 10.1136/jmg.2003.016667 10.1158/1078-0432.CCR-03-0562 10.1136/jcp.2004.022509 10.1038/modpathol.2009.116 10.1038/sj.bjc.6605635 10.2310/7750.2011.11064 10.1038/modpathol.2013.211 10.1155/2015/303791 10.1016/j.jid.2016.05.094 10.1016/j.ygyno.2017.08.023 10.1111/exd.13472 10.1016/j.jaad.2019.07.017 10.1159/000076490 10.1111/j.1365-2133.2009.09251.x 10.1111/j.1365-2133.2008.08687.x 10.5826/dpc.0604a10 10.5826/dpc.0604a05 10.5826/dpc.0802a16 10.1111/jdv.15141
American Journal of Clinical Dermatology; Wohlmuth C, Wohlmuth-Wieser I

Jun 14th, 2021 - Ten percent of all women have pigmented vulvar lesions. Fortunately, most of these are benign but 1% of all melanomas in women affect the vulva. While the mortality rate of cutaneous melanoma has dropped by 7% annually during the last 5 years, the...

Rural melanoma patients in Maryland do not present with more advanced disease than urba...
https://doi.org/10.5070/D327553607
Dermatology Online Journal; Mannschreck DB, Li X et. al.

Jun 13th, 2021 - Rural populations have higher poverty rates, lower educational attainment, higher smoking rates, lower rates of health insurance, higher proportions of elderly individuals, decreased access to health services including dermatology, higher all-caus...

Sun protection behaviors among people living with HIV.
https://doi.org/10.5070/D327553610
Dermatology Online Journal; Kellogg C, Mittal N et. al.

Jun 13th, 2021 - People living with HIV (PLWH) are at increased risk for both melanoma and nonmelanoma skin cancers, but there is currently no data on sun protection behaviors among PLWH. We created a 28-question paper survey to collect information on patient demo...

see more →

Guidelines  181 results

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice r...
https://doi.org/10.1007/s00520-020-05709-1
Supportive Care in Cancer : Official Journal of the Multi... Cooksley T, Girotra M et. al.

Aug 28th, 2020 - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T ...

ESMO consensus conference recommendations on the management of metastatic melanoma: und...
https://doi.org/10.1016/j.annonc.2020.07.004
Annals of Oncology : Official Journal of the European Soc... Keilholz U, Ascierto PA et. al.

Aug 8th, 2020 - The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. Th...

ESMO consensus conference recommendations on the management of locoregional melanoma: u...
https://doi.org/10.1016/j.annonc.2020.07.005
Annals of Oncology : Official Journal of the European Soc... Michielin O, van Akkooi A et. al.

Aug 8th, 2020 - The European Society for Medical Oncology (ESMO) held a consensus conference on melanoma on 5-7 September 2019 in Amsterdam, The Netherlands. The conference included a multidisciplinary panel of 32 leading experts in the management of melanoma. Th...

ASCO20 Virtual Scientific Program Showcases the Latest Advances in Melanoma Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200224/full/
ASCO Daily News;

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a range of studies showcasing the latest advances and clinical breakthroughs in melanoma research.

see more →

Drugs  61 results see all →

Clinicaltrials.gov  64,131 results

'Check Your Assumptions at the Door,' Advises Outlier Patient
https://www.medscape.com/viewarticle/953106

Jun 14th, 2021 - Dr Jacqueline Smith For years, Jacqueline Smith, PhD, had patience with — and a sense of humor about — people who just don't get her medical history and say and do annoying things. A Black woman who developed stage 3 melanoma twice before her 30th...

Regression is significantly associated with outcomes for patients with melanoma.
https://doi.org/10.1016/j.surg.2021.05.010
Surgery Subramanian S, Han G et. al.

Jun 14th, 2021 - The prognostic significance of regression in melanoma is debated. We present a large multicenter study correlating regression with sentinel lymph node metastasis and melanoma-specific survival. The Sentinel Lymph Node Working Group database was re...

Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic st...
https://doi.org/10.1016/j.ejso.2021.06.011
European Journal of Surgical Oncology : the Journal of Th... Helvind NM, Aros Mardones CA et. al.

Jun 14th, 2021 - The use of routine imaging with 18F-FDG PET-CT (PET-CT) in melanoma surveillance is debated and evidence of its diagnostic value and yield in asymptomatic patients is limited. Denmark introduced nationwide routine surveillance with PET-CT in high-...

Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical...
https://doi.org/10.1007/s40257-021-00614-7 10.3322/caac.21590 10.1007/s40257-019-00487-x 10.1002/1097-0142(19930301)71:5<1893::AID-CNCR2820710528>3.0.CO;2-7 10.1111/j.0736-8046.2004.21412.x 10.1001/archderm.1997.03890390083011 10.1111/pde.12838 10.1016/j.jaad.2005.07.034 10.1016/0002-9378(79)90732-4 10.1016/0190-9622(90)70017-C 10.1046/j.1525-1438.2001.01043.x 10.1097/LGT.0000000000000583 10.1002/1097-0142(19950101)75:1<72::AID-CNCR2820750113>3.0.CO;2-G 10.1016/j.jaad.2003.07.026 10.1002/(SICI)1097-0142(19991001)86:7<1273::AID-CNCR24>3.0.CO;2-Z 10.1002/(SICI)1097-0142(19961201)78:11<2353::AID-CNCR13>3.0.CO;2-# 10.1016/j.ygyno.2016.04.021 10.2340/00015555-3103 10.3892/ijmm.2014.1659 10.1038/320415a0 10.1002/j.1460-2075.1987.tb02655.x 10.1200/JCO.2006.06.2984 10.1016/j.humpath.2005.03.015 10.1002/cncr.30473 10.1158/1078-0432.CCR-10-2917 10.1097/PGP.0000000000000636 10.1038/nature05661 10.1016/j.cellsig.2005.06.008 10.1038/onc.2009.320 10.1097/LGT.0000000000000142 10.1016/j.jid.2016.06.011 10.1111/j.1365-2133.2010.10185.x 10.1016/j.jid.2016.05.098 10.1016/j.jaad.2014.03.033 10.1111/j.1365-2133.2009.09558.x 10.4161/21645515.2014.983409 10.1097/PGP.0000000000000454 10.1111/cup.13768 10.1158/1078-0432.CCR-16-2126 10.1097/LGT.0000000000000204 10.1245/s10434-014-4215-3 10.1002/1097-0142(19940515)73:10<2626::AID-CNCR2820731026>3.0.CO;2-U 10.1097/00008390-200412000-00012 10.1016/j.ygyno.2013.02.028 10.1111/ced.14068 10.1111/ajd.12298 10.1016/j.det.2010.08.007 10.1097/00008390-200512000-00011 10.1016/S1470-2045(02)00679-4 10.1001/archdermatol.2011.155 10.1159/000323409 10.1097/IGC.0000000000000198 10.1093/annonc/mdz411 10.1111/j.1525-1438.2007.00788.x 10.1016/0090-8258(92)90300-8 10.1016/j.ygyno.2018.04.562 10.1056/NEJMoa1310460 10.1038/bjc.2014.205 10.1016/j.ygyno.2020.09.044 10.1136/ijgc-2019-000936 10.1016/j.ygyno.2012.11.034 10.1016/j.ygyno.2015.02.014 10.1056/NEJMoa1613210 10.1200/JCO.18.02306 10.1097/MD.0000000000008722 10.1097/00000658-199110000-00013 10.1002/cncr.21611 10.1097/00000421-200206000-00016 10.1200/JCO.2000.18.1.158 10.1056/NEJMoa1003466 10.1056/NEJMoa1709684 10.1056/NEJMoa1503093 10.1056/NEJMoa1412690 10.1200/JCO.2013.53.0105 10.1056/NEJMoa1412082 10.1016/S1470-2045(15)70076-8 10.1056/NEJMoa1414428 10.1056/NEJMoa1504030 10.1200/JCO.2016.67.9258 10.1001/jama.2016.4059 10.1016/S1470-2045(15)00083-2 10.1038/s41416-018-0207-6 10.3390/cancers11081213 10.1038/s41577-019-0224-6 10.1182/blood-2017-07-741025 10.1038/sj.bjc.6602529 10.1002/cncr.21834 10.1038/sj.bjc.6604482 10.1001/jama.2011.746 10.1200/JCO.2012.47.7836 10.1200/JCO.2010.33.9275 10.1158/1078-0432.CCR-14-1630 10.1634/theoncologist.2015-0161 10.1093/annonc/mdx079 10.1007/s10637-011-9763-9 10.1016/j.jid.2017.07.839 10.1158/1078-0432.CCR-11-1987 10.1002/cncr.25766 10.1002/cncr.30663 10.1038/ncponc1251 10.1200/JCO.20.00198 10.1016/j.ctrv.2020.102032 10.1056/NEJMoa1802357 10.1056/NEJMoa1611299 10.1056/NEJMoa1709030 10.1136/jmg.2003.016667 10.1158/1078-0432.CCR-03-0562 10.1136/jcp.2004.022509 10.1038/modpathol.2009.116 10.1038/sj.bjc.6605635 10.2310/7750.2011.11064 10.1038/modpathol.2013.211 10.1155/2015/303791 10.1016/j.jid.2016.05.094 10.1016/j.ygyno.2017.08.023 10.1111/exd.13472 10.1016/j.jaad.2019.07.017 10.1159/000076490 10.1111/j.1365-2133.2009.09251.x 10.1111/j.1365-2133.2008.08687.x 10.5826/dpc.0604a10 10.5826/dpc.0604a05 10.5826/dpc.0802a16 10.1111/jdv.15141
American Journal of Clinical Dermatology; Wohlmuth C, Wohlmuth-Wieser I

Jun 14th, 2021 - Ten percent of all women have pigmented vulvar lesions. Fortunately, most of these are benign but 1% of all melanomas in women affect the vulva. While the mortality rate of cutaneous melanoma has dropped by 7% annually during the last 5 years, the...

Rural melanoma patients in Maryland do not present with more advanced disease than urba...
https://doi.org/10.5070/D327553607
Dermatology Online Journal; Mannschreck DB, Li X et. al.

Jun 13th, 2021 - Rural populations have higher poverty rates, lower educational attainment, higher smoking rates, lower rates of health insurance, higher proportions of elderly individuals, decreased access to health services including dermatology, higher all-caus...

see more →

News  4,253 results

'Check Your Assumptions at the Door,' Advises Outlier Patient
https://www.medscape.com/viewarticle/953106

Jun 14th, 2021 - Dr Jacqueline Smith For years, Jacqueline Smith, PhD, had patience with — and a sense of humor about — people who just don't get her medical history and say and do annoying things. A Black woman who developed stage 3 melanoma twice before her 30th...

Study Findings Support Consideration of Second Biopsy for Transected Melanomas
https://www.medscape.com/viewarticle/952398

Jun 2nd, 2021 - Almost 14% of transected invasive melanoma biopsies at the University of Alabama at Birmingham were up-staged on final surgical pathology, in a review of cases at the university. Had their true Breslow depths been known before definitive surgery, ...

Lifileucel Promising Against Unresponsive Malignant Melanoma
https://www.medscape.com/viewarticle/952183

Jun 1st, 2021 - NEW YORK (Reuters Health) - Lifileucel shows promise in metastatic-melanoma patients whose disease had progressed on standard immune-checkpoint inhibitors (ICI) and other therapies, according to a small open-label trial. "Lifileucel is a ground-br...

'Encouraging' Data on Ipilimumab Plus Anti-PD-1 in Metastatic Melanoma
https://www.medscape.com/viewarticle/952139

May 31st, 2021 - NEW YORK (Reuters Health) - For patients with advanced melanoma resistant to anti-PD-(L)1 monotherapy, combining the CTLA-4 inhibitor ipilimumab with an anti-PD-1 agent "should be favored" over ipilimumab alone as second-line immunotherapy, resear...

Novel Immunotherapy Relatlimab in Advanced Melanoma
https://www.medscape.com/viewarticle/951447

May 18th, 2021 - Adding the novel immune checkpoint inhibitor relatlimab to the more established nivolumab (Opdivo) significantly extended the progression-free survival (PFS) of patients with previously untreated advanced melanoma in comparison with nivolumab alon...

see more →

Patient Education  101 results see all →